Skip to main content
EIKN
NASDAQ Life Sciences

Eikon Therapeutics 公布 2025 年第四季度及全年财务报告，详细介绍临床和公司进展

feedReported by Reuters
Sentiment info
Neutral
Importance info
7
Price
$9.94
Mkt Cap
$537.755M
52W Low
$9.79
52W High
$17.4
Market data snapshot near publication time

summarizeSummary

Eikon Therapeutics 已宣布其 2025 年第四季度及全年财务报告，同时更新了其临床管线和公司发展情况。这则标题作为初始警报，提供了有关公司即将发布的 10-K 和 8-K 文件的重要信息，这些文件预计将在此公告后不久发布。对于像 Eikon 这种市值的生命科学公司，财务表现和临床试验进展是关键的股票驱动因素。交易者将密切关注即将到来的 SEC 文件，以获取具体的财务数据、现金跑道和临床项目的详细信息，从而评估公司的前景和对其股票价格的潜在影响。

在该公告发布时，EIKN的交易价格为$9.94，交易所为NASDAQ，所属行业为Life Sciences，市值约为$5.4亿。 52周交易区间为$9.79至$17.40。 这则新闻被评估为中性市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed EIKN - Latest Insights

EIKN
Mar 30, 2026, 9:51 AM EDT
Source: Reuters
Importance Score:
7
Eikon Therapeutics Reports Q4 and Full Year 2025 Results, Details Clinical and Corporate Progress
Sentiment: Neutral
View Wiseek Article
EIKN
Mar 30, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Eikon Therapeutics Secures $381M Upsized IPO, Extending Cash Runway into 2H 2027 Amidst Clinical Progress
Sentiment: Positive
View Wiseek Article
EIKN
Mar 30, 2026, 7:50 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Eikon Therapeutics Completes Enrollment for Key Phase 2 Lung Cancer Trial
Sentiment: Positive
View Wiseek Article
EIKN
Mar 30, 2026, 7:09 AM EDT
Filing Type: 10-K
Importance Score:
8
Eikon Therapeutics Secures $349M IPO, Advances Clinical Pipeline Amidst Financial Restatement
Sentiment: Neutral
View Wiseek Article
EIKN
Feb 12, 2026, 6:48 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
The Column Group Discloses 11.6% Stake in Eikon Therapeutics, Invests $38.12M in IPO
Sentiment: Positive
View Wiseek Article
EIKN
Feb 10, 2026, 5:06 PM EST
Filing Type: 4
Importance Score:
7
CEO Converts Preferred Stock to Common Stock Ahead of IPO
Sentiment: Positive
View Wiseek Article
EIKN
Feb 09, 2026, 9:19 PM EST
Filing Type: 4
Importance Score:
7
10% Owners Significantly Increase Stake in Eikon Therapeutics with $94.3M Open Market Purchase and Conversions
Sentiment: Positive
View Wiseek Article
EIKN
Feb 06, 2026, 6:33 PM EST
Filing Type: 4
Importance Score:
7
Director Kenneth Frazier Buys $2 Million in Eikon Therapeutics Stock Pre-IPO Completion
Sentiment: Positive
View Wiseek Article
EIKN
Feb 06, 2026, 6:25 PM EST
Filing Type: 4
Importance Score:
9
Director and 10% Owner Group Make Substantial $87.5M Net Stock Acquisition Post-IPO
Sentiment: Positive
View Wiseek Article
EIKN
Feb 05, 2026, 4:05 PM EST
Filing Type: 424B4
Importance Score:
8
Eikon Therapeutics Completes Initial Public Offering, Raising $349 Million Net to Fund Clinical Pipeline
Sentiment: Neutral
View Wiseek Article